Cerity Partners
CNTX icon

Cerity Partners’s Context Therapeutics CNTX Stock Holding History

Cerity Partners’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.2K Buy
40,000
+20,000
+100% +$40.5K ﹤0.01% 3361
2026
Q1 		$52.4K Hold
20,000
– – ﹤0.01% 3109
2025
Q4 		$29.4K Hold
20,000
– – ﹤0.01% 2830
2025
Q3 		$19.4K Hold
20,000
– – ﹤0.01% 2727
2025
Q2 		$13.1K Buy
20,000
+10,000
+100% +$7.19K ﹤0.01% 2615
2025
Q1 		$6.12K Hold
10,000
– – ﹤0.01% 2471
2024
Q4 		$10.5K Hold
10,000
– – ﹤0.01% 2412
2024
Q3 		$19.6K Buy
+10,000
New +$22.2K ﹤0.01% 2513

Other funds holding CNTX

Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Nextech Invest
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Soleus Capital Management
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Octagon Capital Advisors
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Blue Owl Capital Holdings
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Cerity Partners's CNTX Position: Q2 2026 in Review

Cerity Partners increased its Context Therapeutics (CNTX) stake by 100% in Q2 2026, buying an estimated $40.5K and bringing the position to 40,000 shares worth $22.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3361.

Cerity Partners first reported a position in CNTX in Q3 2024 and has held it in 8 quarters since. The position peaked at $52.4K in Q1 2026. 79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

  • Cerity Partners held 40,000 shares of Context Therapeutics worth $22.2K as of Q2 2026.
  • Cerity Partners bought 20,000 Context Therapeutics shares in Q2 2026, an estimated $40.5K.
  • Context Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #3361 holding.
  • Cerity Partners first reported a position in Context Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Cerity Partners's Context Therapeutics position peaked at $52.4K in Q1 2026.
  • 79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.